单克隆抗体治疗急性淋巴细胞白血病
摘要
近年来，肿瘤细胞的单克隆抗体靶向杀伤已成为肿瘤治疗的发展趋势之一。譬如急性淋巴细胞白血病（ALL）细胞表面表达各种特异性抗原CD19，CD20，CD22和CD52等，引发了以这些靶点为目标的新型药物研发。现将就blinatumomab，利妥昔单抗（rituximab），依帕珠单抗（epratuzumab），inotuzumab ozogamicin，阿伦单抗（alemtuzumab）等单抗治疗ALL的临床及临床前研究进行综述。
出处
《国际输血及血液学杂志》
CAS
2012年第5期424-428,共5页
International Journal of Blood Transfusion and Hematology
基金
国家科技支撑计划（2008BA161B01）,中瑞国际合作（天津）子课题（09ZCZDSF03800）
参考文献21
-
1Portell CA, Advani AS. Antibody therapy for acute lymphoblastic leukemia. Curr Hematol Malig Rep, 2012,7 (2) : 153-159.
-
2Thomas DA, Faderl S, O'Brien S, et al. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer, 2006,106(7) : 1569-1580.
-
3Thomas DA, O'Brien S, Faderl S, et al. Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia. J Clin Oncol, 2010, 28 (24) : 3880-3889.
-
4Griffin TC, Weitzman S, Weinstein H, et al. rituximab and ifosfamide, carboplatin, and A study of etoposide chemotherapy in children with recurrent/refractory B-cell (CD20 + ) non- Hodgkin lymphoma and mature B-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group. Pediatr Blood Cancer, 2009,52(2) : 177-181.
-
5Chevallier P, Pigneux A, Robillard N, et al. Rituximah for the treatment of adult relapsed/refractory CD20 positive B-ALL patients., a pilot series. Leuk Res, 2012, 36(3):311-315.
-
6Bargou R, Leo E, Zugmaier G, et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science, 2008,321 (5891) : 974-977.
-
7Topp MS, Kufer P, G6kbuget N, et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy- refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol, 2011,29 (18) : 2493-2498.
-
8Topp M, Goekbuget N, Zugmaier G, et al. Effect of anti-CD19 BiTE blinatumomab on eomplete remission rate and overall survival in adult patients with relapsed/refractory B-precursor ALL. Program and abstracts of the American Society of Clinical Oneology Annual Meeting and Exposition; June 1-5, 2012, Chicago, Illinois. Abstract 6500.
-
9Porter DL, Levine BL, Kalos M,et al. Chimeric antigen receptor- modified T cells in chronic lymphoid leukemia. N Engl J Med, 2011,365(8) : 725-733.
-
10Chatham WW, Wallace DJ, Stohl W, et al. Effect of belimumab on vaccine antigen antibodies to influenza, pneumococcal, and tetanus vaccines in patients with systemic lupus frythematosus in the bliss-76 trial. J Rheumatol, 2012,39(8) :1632-1640.
-
1刘国元.联合应用Alemtuzumab和美罗华治疗复发性及难治性淋巴瘤的经验[J].国外医学（内科学分册）,2004,31(3):136-137.
-
2陆英.早期预测Alemtuzumab对慢性淋巴细胞白血病的治疗效果[J].国外医学（内科学分册）,2004,31(9):412-413.
-
3王巍,赵成海.Epratuzumab治疗Burkitt's淋巴瘤的分子机制[J].现代肿瘤医学,2011,19(11):2188-2190. 被引量：2
-
4StephenMackinnon,MD,边莉.减低预处理毒性(非清髓性)的异基因造血干细胞移植中“Alemtuzumab”(CAMPATH-1H)的作用[J].国外医学（输血及血液学分册）,2003,26(4):298-301.
-
5阎骅(综述),沈志祥(审校).抗CD20单抗治疗CD20＋急性淋巴细胞白血病[J].国际输血及血液学杂志,2009(3):202-204.
-
6王洪武.肿瘤分子靶向治疗进展(四) 肿瘤分子靶向治疗在血液系统肿瘤中的应用[J].中华医学信息导报,2006,21(7):15-15.
-
7朱军.外周T／NK细胞淋巴瘤治疗的进展[J].白血病．淋巴瘤,2010,19(2):65-67. 被引量：1
-
8秦燕（综述）,石远凯（审校）,何小慧（审校）.抗CD22单克隆抗体Epratuzumab治疗非霍奇金淋巴瘤[J].国际肿瘤学杂志,2007,34(3):229-231. 被引量：1
-
9小可（摘译）.alemtuzumab是治疗慢性淋巴细胞白血病的一线药物[J].中华医学信息导报,2008,23(6):7-7.
-
10王洪武.肿瘤分子靶向治疗进展(三) 肿瘤分子靶向治疗在血液系统肿瘤中的应用[J].中华医学信息导报,2006,21(6):15-15.
